Compare SLI & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SLI | GERN |
|---|---|---|
| Founded | 1998 | 1990 |
| Country | Canada | United States |
| Employees | N/A | 258 |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 906.4M | 808.3M |
| IPO Year | 2011 | N/A |
| Metric | SLI | GERN |
|---|---|---|
| Price | $3.98 | $1.26 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 3 |
| Target Price | ★ $5.25 | $2.17 |
| AVG Volume (30 Days) | 1.7M | ★ 13.9M |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $26.91 |
| Revenue Next Year | N/A | $43.75 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.49 | $1.04 |
| 52 Week High | $6.40 | $2.01 |
| Indicator | SLI | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 55.71 | 34.40 |
| Support Level | $3.97 | $1.22 |
| Resistance Level | $4.08 | $1.29 |
| Average True Range (ATR) | 0.23 | 0.06 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 53.37 | 21.15 |
Standard Lithium Corp is engaged in the exploration and development of lithium brine properties in the United States. The company the company's flagship projects are located in the Smackover Formation, a world-class lithium brine asset, focused in Arkansas and Texas. It is also Standard Lithium is advancing the South West Arkansas project, a greenfield project located in southern Arkansas, and strengthening lithium brine prospects in East Texas. Its other project comprises the Lanxess Property Project; and California Properties. The technologies used for the projects are : Direct Lithium Extraction; Demonstration Plant; SiFT; Lithium Sulfide; and Aqualung.
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.